scholarly journals Long-term outcome of autologous stem cell transplantation in light chain deposition disease

2008 ◽  
Vol 23 (6) ◽  
pp. 2052-2057 ◽  
Author(s):  
E. C. Lorenz ◽  
M. A. Gertz ◽  
F. C. Fervenza ◽  
A. Dispenzieri ◽  
M. Q. Lacy ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Light Chain ◽  
Term Outcome ◽  
Light Chain Deposition Disease ◽  
Long Term Outcome ◽  
Light Chain Deposition

Long term outcome of patients with mantle cell lymphoma following autologous stem cell transplantation

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 6660-6660
Author(s):  
E. D. Jacobsen ◽  
D. Neuberg ◽  
D. C. Fisher ◽  
L. M. Nadler ◽  
R. J. Soiffer ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Mantle Cell Lymphoma ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Cell Lymphoma ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Mantle Cell

Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myeloma

2017 ◽  
Vol 98 (6) ◽  
pp. 569-576 ◽  
Author(s):  
Susanna Gassiot ◽  
Cristina Motlló ◽  
Inuska Llombart ◽  
Mireia Morgades ◽  
Yolanda González ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Induction Treatment ◽  
Newly Diagnosed ◽  
Term Outcome ◽  
Long Term Outcome

Prognostic Factors and Long-Term Outcome for Patients with Hodgkin’s Lymphoma Who Relapse after an Autologous Stem Cell Transplantation.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 1649-1649 ◽  
Author(s):  
Mireia Constans ◽  
Anna Sureda ◽  
Reyes Arranz ◽  
Maria Dolores Caballero ◽  
Juan Jose Lahuerta ◽  
...  
Keyword(s):  
Stem Cell ◽  
Prognostic Factors ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Clinical Stage ◽  
Advanced Clinical Stage ◽  
Term Outcome ◽  
Long Term Outcome

Abstract We have analyzed overall survival (OS-REL), progression-free survival (PFS-REL) and the clinical variables influencing the long-term outcome for patients with Hodgkin′s lymphoma (HL) who relapse after an autologous stem cell transplantation (ASCT). From 639 patients autografted for HL [383 males (60%) and 256 (40%) females, median age of 30 (1–66) years] reported to the GEL/TAMO Cooperative Group between January/1984 and January/2003, 175 patients (27%) relapsed at a median time of 10 (4 – 125) months [median (range)] after ASCT. They were 97 males (56%) and 78 (44%) females with a median age of 28 (10 – 66) [median (range)] years at transplantation. Sixty-three patients were autografted in complete remission, 73 in sensitive relapse and 31 in resistant relapse. One hundred and sixty three patients (94%) received different chemotherapy (CT) protocols as conditioning regimen and 12 patients (6%), CT plus total body irradiation. At relapse, 94 patients (53%) presented with advanced stages (III-IV), 49 patients (28%) with B symptoms and 19 (11%) with bulky disease. Relapse was extranodal in 45% of the patient population. Ten percent of the patients had a poor performance status (ECOG ≥2) and 37 patients (22%) had a hemoglobin (Hb) level < 100 g/l at relapse. Thirty four patients (20%) received no further therapy, 107 (60%) received different CT +/− radiotherapy and the remaining 34 patients (20%) were treated with a second stem cell transplantation (13 patients, an ASCT and 21 an allogeneic transplantation). OS-REL and PFS-REL were of 35% ± 4% and 23% ± 4% at 3 years, respectively. Advanced clinical stage (III-IV) at relapse [relative risk (RR) 4.4, 95% confidence interval (CI) (1.7 – 10.8), p = 0.002] and an interval between ASCT and relapse < 12 months [RR 2.4, 95%CI (1.1 – 5.0), p = 0.03] were independent adverse prognostic factors for PFS-REL. Advanced clinical stage at relapse [RR 4.4, 95%CI (1.4 – 14.4), p = 0.012], extranodal disease [RR 2.4, 95%CI (1.3 – 15.4), p = 0.02] and a Hb level < 100 g/l at relapse [RR 3.4, 95%CI (2.0 – 10.4), p = 0.03] were significant adverse prognostic factors for OS-REL. Although the long-term outcome of HL patients who relapse after ASCT is poor, results are better in patients with late relapses and localized disease. Moreover, a minority of the patients can become long-term progression-free survivors after relapse. The identification and construction of prognostic sub-groups according to the number of risk factors may be useful to develop risk-adapted therapeutic strategies.

Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: Long-term outcome of 61 patients from a single institution

2007 ◽  
Vol 48 (10) ◽  
pp. 1968-1975 ◽  
Author(s):  
Carmen Martínez ◽  
Olga Salamero ◽  
Leonor Arenillas ◽  
Juan Duque ◽  
Armando López-Guillermo ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Single Institution ◽  
Term Outcome ◽  
Long Term Outcome

scholarly journals Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma

2008 ◽  
Vol 19 (7) ◽  
pp. 1312-1319 ◽  
Author(s):  
B. Sirohi ◽  
D. Cunningham ◽  
R. Powles ◽  
F. Murphy ◽  
T. Arkenau ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Term Outcome ◽  
Long Term Outcome

Longterm Outcomes and Improved Renal Function with Autologous Stem Cell Transplantation (ASCT) in Light Chain Deposition Disease (LCDD)

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 1198-1198
Author(s):  
Kate Stringaris ◽  
Rabya Sayed ◽  
Helen J Lachmann ◽  
Julian D Gillmore ◽  
Philip N Hawkins ◽  
...  
Keyword(s):  
Renal Function ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Light Chain ◽  
Organ Function ◽  
Light Chain Deposition Disease ◽  
Light Chain Deposition ◽  
Related Mortality

Abstract Background: Light chain deposition disease (LCDD) is a systemic disorder characterized by monoclonal light chain deposition in organs, most often the kidney but also in the liver, heart and nervous system. Treatment aims to suppress the monoclonal plasma cell population producing the light chains to allow for improvement in or delay deterioration of organ function. Treatments are generally modeled on those for myeloma and light chain amyloidosis. The options are cyclical chemotherapy lately using a novel agent based conditioning regime and, in selected patients, high dose melphalan followed by autologous stem cell transplantation. Due to LCDD being an immunoglobulin disease, based on experience with systemic AL amyloidosis, there is a reluctance to consider ASCT due perceived risks of morbidity and transplant related mortality. There is limited data on the safety and outcomes after ASCT in LCDD. We report here the role of autologous stem cell transplantation to treat LCDD in the largest cohort of patients to date. Methods: This study included all patients between 2003 and 2013 with LCDD who had undergone ASCT from the database of the UK National Amyloidosis Centre (NAC). Data on disease status (clonal markers and organ involvement) at diagnosis, pre and post ASCT was collected from the respective transplant centres for patient progress during and immediately after ASCT. Organ function and clonal response data were serially collected for all patients including clinical course, renal, cardiac and neurological function. Results: A total of ten patients with LCDD were identified who underwent ASCT. This accounted for 23% of all LCDD patients seen at the NAC over this time period. The baseline characteristics were: median age 48 (range 36-60), eGFR 17 ml/min (<10-51), Alkaline phosphatise 92 (51-334), LV wall thickness 10 mm, NT-proBNP 1121 (range 318-4346). Serum monoclonal M protein was quantifiable in 2/10 patients. 9/10 patients had elevated kappa serum free light chains (SFLC) with median level of 1069 mg/dl (range 281-2962) with median κ/λ ratio of 21 (range 0.1-151, NR 0.26-1.65). Only 1/10 had elevated lambda LC. All patients had clonal plasma cells on marrow aspirate with 5/10 patients having >10% (median 15; range 12-50%) and 5/10 , </= 10% (range 2-10%). All patients received chemotherapy prior to ASCT. The median time from diagnosis to ASCT was 13.5 months (Range 4-27). Median follow up post ASCT was 4.8 years (range 6 months-11 years). Haematological responses were seen in all patients with 7/10 acheiving a complete clonal response, 1 patient achieving a VGPR and 2 patients achieving PR. All patients had renal impairment prior to ASCT and 5/10 were on renal dialysis. There was no transplant related mortality and all patients are still alive. After ASCT, 4 patients’ renal function improved, 4/5 remained unchanged on dialysis and 2 patients showed a deterioration in renal function. Of the patients whose renal function improved, one came off dialysis post ASCT, the other three were not on dialysis at any time point. Of the two patients whose renal function deteriorated post ASCT, one required dialysis 3 years after ASCT. Conclusion: This largest study of autologous stem cell transplantation in LCDD to date shows a very high clonal response rate post ASCT. 50% patients had improvement in renal function after transplant. ASCT in LCDD is safe with no transplant related mortality. None of the patients progressed to active myeloma after ASCT. This data supports the use of ASCT in patients with LCDD. Given the rarity of the condition, international registry data would be important to confirm these encouraging findings. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document